Fate Therapeutics, Inc.
FATE
$1.06
-$0.07-6.20%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.65M | 7.14M | 8.47M | 13.34M | 13.63M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.65M | 7.14M | 8.47M | 13.34M | 13.63M |
| Cost of Revenue | 68.29M | 75.93M | 84.75M | 86.16M | 89.16M |
| Gross Profit | -61.64M | -68.80M | -76.28M | -72.83M | -75.53M |
| SG&A Expenses | 61.35M | 67.59M | 77.75M | 83.56M | 90.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 153.25M | 167.13M | 186.11M | 199.09M | 209.17M |
| Operating Income | -146.60M | -159.99M | -177.64M | -185.75M | -195.54M |
| Income Before Tax | -136.32M | -156.09M | -171.52M | -175.88M | -186.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -136.32 | -156.09 | -171.52 | -175.88 | -186.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -136.32M | -156.09M | -171.52M | -175.88M | -186.26M |
| EBIT | -146.60M | -159.99M | -177.64M | -185.75M | -195.54M |
| EBITDA | -133.70M | -145.34M | -161.61M | -168.28M | -176.58M |
| EPS Basic | -1.15 | -1.32 | -1.45 | -1.49 | -1.65 |
| Normalized Basic EPS | -0.71 | -0.75 | -0.83 | -0.85 | -0.95 |
| EPS Diluted | -1.15 | -1.32 | -1.45 | -1.49 | -1.65 |
| Normalized Diluted EPS | -0.71 | -0.75 | -0.83 | -0.85 | -0.95 |
| Average Basic Shares Outstanding | 475.15M | 473.70M | 472.47M | 471.41M | 454.14M |
| Average Diluted Shares Outstanding | 475.15M | 473.70M | 472.47M | 471.41M | 454.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |